Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Pilot Study of Feasibility, Safety, and Economics of Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Non-APL Acute Myeloid Leukemia
RATIONALE: Gathering information about patients with myelodysplastic syndrome or acute myeloid leukemia who are discharged after finishing chemotherapy, or who stay in the hospital until blood counts return to normal, may help doctors learn more about a patient's quality of life, use of medical services, and the cost of these services.
PURPOSE: This clinical trial is studying early discharge and outpatient care in patients who have undergone chemotherapy for myelodysplastic syndrome or acute myeloid leukemia.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
OBJECTIVES:
Primary
- To compare the death rate in patients with myelodysplastic syndromes or acute myeloid leukemia who are discharged after completion of induction chemotherapy vs those who remain in the hospital until blood counts recover.
Secondary
- To determine the proportion of patients who meet the early discharge criteria after completion of induction chemotherapy.
- To compare the costs incurred by patients who are discharged early vs those who are discharged only after blood counts recover.
- To compare resource utilization (e.g., transfusions) among these patients.
- To compare the quality of life of these patients.
OUTLINE: Within 72 hours after completion of induction chemotherapy, patients are either discharged from the hospital or remain in the hospital until their blood counts recover.
Patients receive standard supportive care after completion of induction chemotherapy either in the hospital or as an outpatient. Outpatients are seen by a registered nurse or physician assistant ≥ 3 times weekly and by a physician at least once weekly.
A medical chart review is conducted to obtain information about medical complications (e.g., neutropenic fever, documented infections, bleeding, reasons for hospitalization) and use of medical resources. Patients complete the MDA Symptom Inventory and the EORTC QLQ-C30 questionnaire periodically to assess quality of life. Costs associated with inpatient and outpatient care are evaluated using electronic billing information from the University of Washington Medical Center and Seattle Cancer Care Alliance.
After completion of the study, patients are followed up for 1 month.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97201-3098
- Oregon Health and Science University
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109-1024
- Fred Hutchinson Cancer Research Center
-
-
-
-
-
Basel, Suiza, CH-4031
- Clinical Cancer Research Center at University Hospital Basel
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Diagnosis of one of the following:
- Myelodysplastic syndromes
Acute myeloid leukemia (AML)
- No acute promyelocytic leukemia with t(15;17)(q22;q12), PML/RAR, or other variants
- Planning to undergo AML-like intensive induction chemotherapy (e.g., "7+3" or regimen with similar or higher intensity) for untreated or relapsed disease within 1 week after study entry OR has started therapy within the past 72 hours
PATIENT CHARACTERISTICS:
- No hypersensitivity or allergy to fluoroquinolones, triazoles, or acyclovir
- ECOG/WHO/ZUBROD performance status 0-1*
- Total bilirubin ≤ 2.5 times upper limit of normal (ULN) (unless elevation is thought to be due to Gilbert's syndrome or hemolysis)*
- AST and ALT ≤ 1.5 times ULN*
- Serum creatinine ≤ 1.5 times ULN*
- No clinical evidence of congestive heart failure*
- No active bleeding*
- Not refractory to platelet transfusions (e.g., due to HLA-alloimmunization)*
- No requirement for IV antimicrobial therapy*
- Agrees to undergo close follow-up that includes ≥ 3 visits per week at the Seattle Cancer Care Alliance (SCCA)*
- Has a confirmed reliable caregiver and transportation*
- Confirmed temporary or permanent residency within a 30-minute commute from the University of Washington (UW) Medical Center/SCCA*
- Has identified a UW/SCCA hematologist/oncologist who is willing to care for the patient in the outpatient clinic* NOTE: *Additional criteria for early discharge from the hospital
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
|---|
|
Death rate in patients discharged after completion of induction chemotherapy
|
|
Rate of successful discharge of patients who meet medical discharge criteria
|
|
Costs associated with outpatient vs inpatient treatment
|
|
Medical resources used with outpatient vs inpatient treatment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Roland Walter, MD, PhD, Fred Hutchinson Cancer Center
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- síndromes mielodisplásicos de novo
- síndromes mielodisplásicos previamente tratados
- síndromes mielodisplásicos secundarios
- leucemia mieloide aguda en adultos con anomalías 11q23 (MLL)
- leucemia mieloide aguda en adultos con inv(16)(p13;q22)
- leucemia mieloide aguda en adultos con t(16;16)(p13;q22)
- leucemia mieloide aguda en adultos con t(8;21)(q22;q22)
- leucemia mieloide aguda recurrente en adultos
- leucemia mieloide aguda en adultos no tratada
- leucemia megacarioblástica aguda del adulto (M7)
- adulto leucemia mieloide mínimamente diferenciada aguda (M0)
- leucemia monoblástica aguda del adulto (M5a)
- leucemia monocítica aguda del adulto (M5b)
- leucemia mieloblástica aguda del adulto con maduración (M2)
- leucemia mieloblástica aguda del adulto sin maduración (M1)
- leucemia mielomonocítica aguda del adulto (M4)
- leucemia basófila aguda del adulto
- leucemia eosinofílica aguda del adulto
- eritroleucemia del adulto (M6a)
- leucemia eritroide pura del adulto (M6b)
- leucemia mieloide aguda con displasia multilinaje después del síndrome mielodisplásico
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2300.00
- P30CA015704 (Subvención/contrato del NIH de EE. UU.)
- FHCRC-2300.00
- IR 6845
- CDR0000631997 (Identificador de registro: PDQ)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre revisión de la historia clínica
-
Schön Klinik Berchtesgadener LandTerminadoAfección pulmonar obstructiva crónicaAlemania
-
Schön Klinik Berchtesgadener LandTerminadoAfección pulmonar obstructiva crónicaAlemania
-
Matthew EagletonMassachusetts General HospitalInscripción por invitaciónDisección aórtica | Disección aórtica ascendente | Aneurisma de aorta toracoabdominal | Aneurismas de la aorta torácica | Disección, Aneurisma | Aneurisma de la aorta ascendente | Arco aórtico; Aneurisma De Disección | Aneurisma de la arteria renal | Aneurisma de la arteria mesentérica superiorEstados Unidos
-
Indiana UniversityAún no reclutando
-
Abbott Medical DevicesTerminado
-
Abbott Medical DevicesTerminado
-
Soterix MedicalGeorgetown University; National Institute of Neurological Disorders and Stroke... y otros colaboradoresTerminado
-
University of Nove de JulhoMulti Radiance MedicalReclutamientoDolor de rodilla crónicoBrasil
-
General University Hospital, PragueTerminado
-
Soterix MedicalNYU Langone HealthTerminadoDepresión resistente al tratamiento | Depresión unipolarEstados Unidos